Iron overload: what is the role of public health?

[1]  D. Swinkels,et al.  Diagnosis and management of hereditary haemochromatosis , 2011, BMJ : British Medical Journal.

[2]  P. Malfertheiner,et al.  A Phase 1/2, Dose-Escalation Trial of Deferasirox for the Treatment of Iron Overload in HFE-Related Hereditary Hemochromatosis , 2010, Hepatology.

[3]  E. Vichinsky,et al.  Iron Metabolism and Iron Chelation in Sickle Cell Disease , 2009, Acta Haematologica.

[4]  Ian H. Frazer,et al.  Common variants in TMPRSS6 are associated with iron status and erythrocyte volume , 2009, Nature Genetics.

[5]  J. Barton,et al.  HAMP promoter mutation nc.-153C>T in 785 HEIRS Study participants , 2009, Haematologica.

[6]  D. English,et al.  HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis‐related morbidity , 2009, Hepatology.

[7]  P. Malfertheiner,et al.  187 A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION TRIAL USING THE ONCE-DAILY ORAL CHELATOR DEFERASIROX TO TREAT IRON OVERLOAD IN HFE-RELATED HEREDITARY HEMOCHROMATOSIS: FINAL RESULTS , 2009 .

[8]  W. Rogowski.  The Cost-Effectiveness of Screening for Hereditary Hemochromatosis in Germany: A Remodeling Study , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

[9]  D. English,et al.  The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. , 2008, Gastroenterology.

[10]  H. Bonkovsky,et al.  Hereditary Hemochromatosis: Time for Targeted Screening , 2008, Annals of Internal Medicine.

[11]  D. Reboussin,et al.  Serum ferritin concentrations and body iron stores in a multicenter, multiethnic primary‐care population , 2008, American journal of hematology.

[12]  M. Knutson,et al.  The Hereditary Hemochromatosis Protein, HFE, Inhibits Iron Uptake via Down-regulation of Zip14 in HepG2 Cells* , 2008, Journal of Biological Chemistry.

[13]  P. Lavori,et al.  Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. , 2008, Journal of the National Cancer Institute.

[14]  D. English,et al.  Iron-overload-related disease in HFE hereditary hemochromatosis. , 2008, The New England journal of medicine.

[15]  A. Verbeek,et al.  Morbidity and mortality in first-degree relatives of C282Y homozygous probands with clinically detected haemochromatosis compared with the general population: the HEmochromatosis FAmily Study (HEFAS). , 2007, The Netherlands journal of medicine.

[16]  C. McLaren,et al.  Genetic screening for iron overload: No evidence of discrimination at 1 year. , 2007, The Journal of family practice.

[17]  B. Snively,et al.  A genome‐wide linkage scan for iron phenotype quantitative trait loci: the HEIRS Family Study , 2007, Clinical genetics.

[18]  J. Barton.  Chelation therapy for iron overload , 2007, Nutrition reviews.

[19]  P. Lavori,et al.  Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. , 2007, JAMA.

[20]  E. Harris,et al.  Screening for Hereditary Hemochromatosis: A Systematic Review for the U.S. Preventive Services Task Force , 2006, Annals of Internal Medicine.

[21]  B. Nordestgaard,et al.  The penetrance of hereditary hemochromatosis. , 2005, Best practice & research. Clinical haematology.

[22]  E. Thomson,et al.  Hemochromatosis and iron-overload screening in a racially diverse population. , 2005, The New England journal of medicine.

[23]  B. Wells,et al.  Association of ferritin and lipids with C-reactive protein. , 2004, The American journal of cardiology.

[24]  Christopher F. Martin,et al.  Insurance, employment, and psychosocial consequences of a diagnosis of hereditary hemochromatosis in subjects without end organ damage , 2003, American Journal of Gastroenterology.

[25]  P. H. Moghaddam,et al.  No increase in mortality and morbidity among carriers of the C282Y mutation of the hereditary haemochromatosis gene in the oldest old: the Leiden 85‐plus Study , 2002, European journal of clinical investigation.

[26]  V. Felitti,et al.  Prevalence of hemochromatosis-related symptoms among individuals with mutations in the HFE gene. , 2002, Mayo Clinic proceedings.

[27]  A. Donovan,et al.  Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. , 2001, The Journal of clinical investigation.

[28]  Cornelia M. van Duijn,et al.  A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis , 2001, Nature Genetics.

[29]  K Takada,et al.  A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. , 2001, American journal of human genetics.

[30]  L. Grummer-Strawn,et al.  Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. , 2001, JAMA.

[31]  Lisa M. Schwartz,et al.  Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. , 2000, American heart journal.

[32]  Paolo Gasparini,et al.  The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22 , 2000, Nature Genetics.

[33]  J. Olynyk,et al.  A population-based study of the clinical expression of the hemochromatosis gene. , 1999, The New England journal of medicine.

[34]  I. Fellows,et al.  Haemochromatosis gene C282Y homozygotes in an elderly male population , 1999, The Lancet.

[35]  James Barton,et al.  Management of Hemochromatosis , 1998, Annals of Internal Medicine.

[36]  C. Barash,et al.  Screening for hemochromatosis. , 1993, The New England journal of medicine.

[37]  J. Sullivan.  IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK , 1981, The Lancet.

[38]  M. Bulsara,et al.  Hereditary hemochromatosis is characterized by a clinically definable arthropathy that correlates with iron load. , 2011, Arthritis and rheumatism.

[39]  Jia Ji-don.  EASL clinical practice guidelines for HFE hemochromatosis. , 2010, Journal of hepatology.

[40]  A. Verbeek,et al.  Severity of iron overload of proband determines serum ferritin levels in families with HFE-related hemochromatosis: the HEmochromatosis FAmily Study. , 2009, Journal of hepatology.

[41]  D. Reboussin,et al.  Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. , 2008, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[42]  Marie-Pierre Dubé,et al.  Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis , 2004, Nature Genetics.

[43]  D. Girelli,et al.  Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis , 2003, Nature Genetics.